Ann: Clarity enters into Clinical Supply Agreement, page-5

Am I wrong to read this as a reference to Fusion (a recent US$1.4billion buyout by Astra Zeneca)!

"... Alpha-emitter therapies, such as those involving actinium-225 (Ac-225or ²²⁵Ac) and lead-212 (Pb-212 or ²¹²Pb), are generatinginterest,BUT;

a) Their commercialsupply chains are still in the early development phase, and they arecurrently very difficult to source.

b) They are YET TOSHOWsafety and efficacy in late-stage trials, as opposed to betaemitters, like Cu-67, that have a long history of effectiveness in treatingsolid tumors...."

If so (and I think it is) - GREAT!